Across TCGA pan-cancer cohorts, MIR218-1 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated MIR218-1 data layer.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher MIR218-1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MIR218-1 expression acts as an unfavorable survival marker, although some lineages such as PAAD and KICH show a favorable association.
LUSC, PAAD, and THYM are the cancer types where MIR218-1 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.